【レポートの概要(一部)】
1. Report Overview
1.1 Overview of Biosimilar Monoclonal Antibodies: R&D, Industry and Market
1.2 Why You Should Read this Report
1.3 How This Study Delivers
1.4 Main Questions Answered by the Analysis
1.5 Who is This Investigation For?
1.6 Method of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Associate visiongain Reports
1.9 About visiongain
2. Introduction to Biosimilar Monoclonal Antibodies
2.1 Natural Antibodies: Key to the Immune System
2.2 From Serum therapy to Monoclonal Antibodies
2.3 Humanising the mAb
2.4 Biologics (Biological Drugs) and Biosimilars
2.5 Why are Biosimilars in High Demand?
2.6 Considerations for the Development of Biosimilars
2.6.1 Biologics and Biosimilars Are Large, Complex Molecules
2.6.2 How Much of a Concern is Immunogenicity?
2.7 Biosimilar Monoclonal Antibodies Currently on the Market
3. The Global Market for Biosimilar Monoclonal Antibodies, 2016-2026
3.1 The Present Global Market for Biosimilar Monoclonal Antibodies
3.2 The Global Market for Biosimilar mAbs: A Revenue Forecast, 2016-2026
3.3 The Global Market for Biosimilar mAbs by Compound: Predictions for Revenue and Market Share in 2020 and 2026
3.4 The World Market for Biosimilar mAbs by Compound: Revenue Forecasts, 2016-2026
3.4.1 Will Biosimilar Versions of Monoclonal Antibodies Capture a Large Proportion of the Market?
3.4.2 Biosimilar Infliximab: Currently the Second Largest Submarket
3.4.2.1 Biosimilar Infliximab Revenue Forecast 2016-2026
3.4.3 Biosimilar Rituximab: The current Leading Submarket Driven by Sales in Russia
3.4.3.1 Biosimilar Rituximab: Revenue Forecast 2016-2026
3.4.4 Biosimilar Abciximab: Revenue Forecast 2016-2026
3.4.4.1 Biosimilar Abciximab: Revenue Forecast, 2016-2026
3.4.5 Biosimilar Trastuzumab: Pipeline Rich in Phase III Candidates
3.4.5.1 Biosimilar Trastuzumab: Revenue Forecast, 2016-2026
3.4.6 Biosimilar Adalimumab: Patents Hold Back Revenue on a Large Pipeline
3.4.6.1 Biosimilar Adalimumab: Revenue Forecast 2016-2026
3.4.7 Biosimilar Bevacizumab: Will Late Entry to the Biosimilar mAb Market Restrict Revenue?
3.4.7.1 Biosimilar Bevacizumab: Revenue Forecast, 2016-2026
3.5 Drivers and Restraints for the Biosimilar mAb market 2016-2026
3.5.1 Driving Factors of the Biosimilar mAb Market 2016-2026
3.6 Restraining Factors of the Biosimilar mAb Market 2016-2026
4. Individual Biosimilar mAb Products: Marketed and Pipeline Drugs, 2016-2026
4.1 Biosimilar mAbs on the Market in 2015
4.1.1 Celltrion’s Remsima/ Hospira’s Inflectra. Egis’ Flammegis (Infliximab): The First Official Biosimilar Monoclonal Antibody
4.1.1.1 Remsima/Inflectra/Flammegis Revenue Forecast, 2016-2026
4.1.2 Infimab (Infliximab): Launched a Quarter Ahead of Schedule
4.1.2.1 Infimab Revenue Forecast ($m) 2016-2026
4.1.2.2 Dr Reddy’s Reditux (Rituximab): No Application for EU or US Approval
4.1.2.3 Reditux Revenue Forecast, 2016-2026
4.1.3 Intas Pharmaceuticals’ Mabtas (Rituximab)
4.1.3.1 Mabtas (Rituximab) Revenue Forecast 2016-2026
4.1.4 AcellBia (Rituximab): Sales in Russia Generating Large Revenue Figures
4.1.4.1 AcellBia Revenue Forecast 2016-2026
4.1.5 MABALL: Faces Competition from other Biosimilar Rituximabs in India
4.1.5.1 MABALL Revenue Forecast, 2016-2026
4.1.6 Isu Abxis’ Clotinab (abciximab):
4.1.6.1 Clotinab Revenue Forecast, 2016-2026
4.1.7 AbcixiRel: The First Indian Abciximab Biosimilar
4.1.7.1 AbcixiRel Revenue Forecast 2016-2026
4.1.8 Herzuma (Trastuzumab): Approved in South Korea
4.1.8.1 Herzuma Revenue Forecast 2016-2026
4.1.9 CANMAb/Hertraz (Trastuzumab)
4.1.9.1 CANMAb/Hertraz Revenue Forecast, 2016-2026
4.2 Pipeline Biosimilars
4.2.1 BI695500 (Rituximab): An EU Launch Anticipated in 2017
4.2.1.1 BI695500 Revenue Forecast, 2016-2026
4.2.2 CT-P10 (Rituximab): Celltrion’s Reputation for Biosimilars will Assist Sales
4.2.2.1 Celltrion’s CT-P10 (Rituximab) Revenue Forecast, 2016-2026
4.2.3 Boehringer Ingelheim’s BI695501 (Adalimumab)
4.2.3.1 BI695501 Revenue Forecast, 2016-2026
4.2.4 BCD-022 (Trastuzumab): Currently under Development in Russia Only
4.2.4.1 BCD-022 Revenue Forecast, 2016-2026
4.2.5 Fujifilm Kyowa Kirin Biologics’ FKB327 (Adalimumab)
4.2.5.1 FKB327 Revenue Forecast, 2016-2026
4.2.6 Fujifilm Kyowa Kirin Biologics’ FKB238 (Bevacizumab)
4.2.6.1 Fujifilm Kyowa Kirin Biologics’ FKB238 Revenue Forecast 2016-2026
4.2.7 BCD-021 (Bevacizumab): Russia Will Contribute the Most Revenue
4.2.7.1 BCD-021 Revenue Forecast 2016-2026
5. Leading National Markets for Biosimilar Monoclonal Antibodies
5.1 What Were the Leading National Markets for Biosimilar mAbs in 2015?
5.2 How Will National Market Shares Change Over the Forecast Period?
5.3 India: The Current Leading Nation for Biosimilar mAbs but Growth will Slow
5.3.1 India Releases New Biosimilar Development Guidelines
5.3.2 Indian Biosimilar Submarket Forecast 2016-2026
5.4 Russia: Lack of Regulatory Framework Works Well in the Short Term
5.4.1 Russian Government Backed ‘Pharma 2020’ Initiative
5.4.2 Russian Biosimilar mAb Revenue Forecast, 2016-2026
5.4 South Korean Market has Benefitted from Early Biosimilar Guidelines
5.4.1 Significant Investment in Biosimilars in South Korea
5.4.2 South Korean Biosimilar mAb Revenue Forecast, 2016-2026
5.5 China: A Fragmented Biosimilar mAb Market
5.5.1 Chinese FDA Publishes Finalised Biosimilar Guidelines in 2015
5.5.2 China Biosimilar mAb Revenue Forecast, 2016-2026
5.6 Brazil: ANVISA’s Biosimilar Regulations Are Similar the EMA’s
5.6.1 Brazil Biosimilar mAb Revenue Forecast 2016-2026
5.7 The Outlook for Biosimilar mAbs in the EU 2016-2026
5.7.1 Updating Biosimilar Regulation: Guidelines for the Specific Approval of Biosimilar mAbs
5.7.2 Biosimilar mAbs in the EU5: Revenue Forecasts, 2016-2026
5.7.3 Germany: the Current EU Leader
5.7.4 France: Will the Uptake of Biosimilar mAbs be Restricted?
5.7.5 UK: NICE Recommends Use of Remsima for Certain Indications
5.7.6 Italy: Healthcare Spending Cuts Will Drive Growth
5.7.7 Spain: High Biosimilar mAb Discounts Expected
5.8 The Outlook for Biosimilar mAbs in Japan
5.8.1 Regulations for Naming Biosimilars
5.8.2 Biosimilar mAb Market Activity in Japan
5.8.3 Japanese Biosimilar Submarket Forecast 2016-2026
5.9 US Biosimilar mAb Outlook: None Currently on the Market
5.9.1 US FDA Biosimilar Guidelines were Released in 2015
5.9.2 Legal Challenges for Biosimilars in the US
5.9.3 State Regulation of Biosimilar Substitution
5.9.4 The US Biosimilar mAb Market Revenue Forecast, 2016-2026
6. Leading Companies in Biosimilar Monoclonal Antibodies
6.1 Collaboration in Biosimilar mAb Development
6.2 BioXpress: Targeting Patent Expiry Dates in 2019-2023
6.3 Celltrion: Company’s Market Value Surges to Exceed $10.7bn
6.4 Harvest Moon: Six Compounds Under Development
6.5 Genor Biopharma: A Biosimilar mAb Market Leader in China
6.6 Samsung Bioepsis
6.7 Mabion: Poland’s Leading Biosimilar mAb Developer
6.8 Gene Techno Science: Substantial Revenue Increases Since 2014
6.9 India’s Biocon:
6.10 Coherus Biosciences
6.11 BIOCAD: World Leader Biosimilar Rituximab Sales
6.12 Big Pharma and the Biosimilar mAb Market
6.13 Significant Acquisitions in the Biosimilar mAb Market
6.13.1 Pfizer Acquires Hospira
6.13.2 Epirus Acquires Bioceros
7. Qualitative Analysis of Biosimilar Monoclonal Antibodies
7.1 Strengths and Weaknesses of the Biosimilar Monoclonal Antibody Market, 2016-2026
7.1.1 Global Demand for Affordable Biopharmaceuticals has Never Been Greater
7.1.2 Adoption of Biosimilar mAbs will be Proportional to the Rate of Discount
7.1.3 Approval Pathways are Now Established in Developed Markets
7.1.4 Complexity of Protein Molecules Leads to Technical Challenges
7.1.5 Doctor and Patient Confidence May Take Time
7.2 Opportunities and Threat Facing the Biosimilar Monoclonal Antibody Market, 2016-2026
7.2.1 Market Opportunities from Patent Expiries and a Well-stocked Pipeline
7.2.2 Substitution may Not Occur Automatically
7.2.3 Biobetters Offer a Serious Threat to the Production and Uptake of Biosimilars
7.3 Social and Technological Forces Influencing the Biosimilar Monoclonal Antibodies Market 2016-2026
7.3.1 Social Factors: Driving or Restraining the Market?
7.3.2 Technological Factors Concentrate on Reducing Costs and Increasing Ease of Production
7.3.3 Economic Pressures Raise Demand for Biosimilar mAbs
7.3.3.1 Fragmentation of the Market Could Limit Individual Drug Revenues
7.3.4 Political Issues: Stringent Regulations Hurdles to Market Entry
8. Research Interviews
8.1 Interview with Professor Steve Morgan, UBC
8.1.1 On the Benefits of mAbs
8.1.2 On the FDA Biosimilar Regulatory Pathway
8.1.3 On the Challenges in Bringing Biosimilar mAbs to Market
8.1.4 On the Rate of Uptake of Biosimilar mAbs
8.1.5 On What Can be Learnt From Previous Case Studies
8.2 Interview with Dr. Seoyoung C. Kim, Harvard
8.2.1 On the use of Remsima in Korea
8.2.2 On Adoption Rates of Biosimilar Infliximab in the US
8.2.3 On the Indications for Biosimilar Infliximab
9. Conclusions From our Study
9.1 Biosimilar Monoclonal Antibodies: World Market, 2016-2026
9.2 Future of Compounds on the Market and in the Pipeline
9.3 Leading National Markets for Biosimilar Monoclonal Antibodies 2016-2026
9.4 Leading Companies in the Biosimilar mAb Market
9.5 Current and Expected Industry Trends 2016-2026
9.5.1 Cost Control of Healthcare Will Work in Favour mAbs
9.5.2 Upcoming Patent Expiries in Developed Markets Offer Large Market Potential
9.5.3 Complex Production Processes are a Restraining Factor
9.5.4 Clinician and Patient Confidence Must be Maximised to Ensure Uptake
9.5.5 Biobetters Pose a Threat
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
【レポート販売概要】
■ タイトル:バイオシミラー・モノクローナル抗体の世界市場:インフリキシマブ、リツキシマブ、トラスツズマブ、アダリムマブ、ベバシズマブ、アブシキシマブ■ 英文:Biosimilar Monoclonal Antibodies Market Forecast 2016-2026 : Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab
■ 発行日:2016年2月
■ 調査会社:visiongain
■ 商品コード:VGAIN6041527
■ 調査対象地域:グローバル
- 世界のナノテクノロジーを用いたドラッグデリバリー市場動向(2012-2016)TechNavio's analysts forecast the Global Nanotechnology Drug Delivery market to grow at a CAGR of 73.97 percent over the period 2012-2016. One of the key factors contributing to this market growth is the low R&D cost. The Global Nanotechnology Drug Delivery market has also been witnessing an increase in customer support services. However, the increasing safety concerns could pose a challenge to th …
- Chaparral Energy, Inc.:石油・ガスバリューチェーン分析レポート2013Chaparral Energy, Inc. Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "Chaparral Energy, Inc." Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “Chaparral Energy, Inc.”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chain. The repor …
- 世界のアデノウイルス検査市場The report presents a detailed analysis of the Adenovirus diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Adenovirus definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals - Co …
- ヘルスケア予測分析の世界市場規模・予測:用途別(オペレーションマネジメント、財務、人々の健康、臨床)、エンドユーザー別(支払者、提供者)、地域別(北アメリカ、ヨーロッパ、アジア太平洋、ラテンアメリカ、MEA)、セグメント予測、2014-2025The global healthcare predictive analytics market is expected to reach USD 19.5 billion by 2025, according to a new report by Grand View Research, Inc. Healthcare costs are increasing day by day and are anticipated to increase further. For instance, as per the IBM Global Business Services executive report in 2014, the per capita health expenditure of the U.S. was around USD 9,400 which was almost …
- 世界の自動車シートベルト(Seat Belts)市場動向(2012-2016)TechNavio's analysts forecast the Global Automotive Seatbelts market to grow at a CAGR of 4.41 percent over the period 2012-2016. One of the key factors contributing to this market growth is the improved safety. The Global Automotive Seatbelts market has also been witnessing the increased adoption of inflatable seatbelts. However, the economic instability in many countries could pose a challenge t …
- クロロプレンゴム(CR)の世界市場2015-2019About Chloroprene Rubber Chloroprene rubber (CR) is an artificial polymer, which acts as an elastomer. Elastomers can experience significantly greater elastic deformation under anxiety and recovers its previous size without permanent deformation. CR has great mechanical quality, high ozone and weather resistance, great aging resistance, low flammability, great resistance toward chemicals, moderate …
- 世界の飼料用酵素市場:フィターゼ、プロテアーゼ、非澱粉性多糖類酵素Feed enzymes are obtained through natural sources and have become the most important part of the livestock’s feed. They are increasingly used in markets where the consumption of feed is increasing. The invention of high- and rich-quality feed enzymes is an opportunity for the key players to innovate and bring changes in their current product portfolio. The report includes the market size in terms …
- フォームフィルシール(FFS)充填機の世界市場予測(~2020)The form-fill-seal market size is projected to grow from USD 16.99 Billion in 2015, to USD 21.55 Billion by 2020, at a CAGR of 4.87% from 2015 to 2020. The form-fill-seal market is increasing proportionally with the overall packaging equipment industry and growth in flexible packaging industry. The market is primarily driven by factors such as improving economic conditions of countries, technologi …
- 世界の女性用インティメートケア製品市場:流通経路別、地域別Global Women’s Intimate Care Products: About this market Technavio’s women’s intimate care products market analysis considers sales from both offline and online distribution channels. Our study also finds the sales of women’s intimate care products in APAC, Europe, MEA, North America, and South America. In 2019, the offline segment had a significant market share, and this trend is expected to cont …
- 世界の菓子類市場のニュース及びイベント動向(2014年7月)Synopsis The report provides a review of the latest news and key events in the global confectionery market during July 2014. Summary Using this report, marketers will effectively gain an insight into the latest happenings in the global confectionery market throughout the month. The monthly report provides the reader with the top-line data necessary to quickly keep abreast of latest events in the g …
- クラウド型ネットワークサービスの世界市場2016-2020About Network-as-a-service NaaS is a virtual networking business model that refers to the delivery of networking resources, services, and applications over the Internet. Clients include individual businesses and enterprises that compensate the service provider on a pay-per-use basis. NaaS (or cloud-based electronic networking) has emerged as a new way to build cost-effective, dynamic, and flexible …
- 自動車内装材の世界市場予測(~2021年):合成皮革、皮革、熱可塑性ポリマ、織物“High demand from automotive industry is driving the automotive interior materials market”The market size for automotive interior materials is projected to reach USD 98.76 billion by 2021, registering a CAGR of 11.8% between 2016 and 2021. Increasing demand from the automotive industry is the major driver for the automotive interior materials market. The global automotive interior materials indust …
- 世界のデジタル経済動向(Eヘルス、電子政府、デジタル教育など):Global Digital Economy – E-Health, E-Government and E-Education Essential to the FutureTechnology developments now shape the future for health, education and governmentBuddeComm has been predicting for at least the last 20 years that major changes in technology will have massive social and economic implications. Unlike previous ‘revolutions’ that changed the world, this ‘digital revolution’ is unfolding within a short timeframe of 20-30 years. Compare this to the industrial revoluti …
- 3Dプリンティング用ガスの世界市場:アルゴン、窒素MarketsandMarkets projects that the 3D Printing Gases Market/Additive Manufacturing Gases Market size is to grow from USD 26.92 Million in 2015 to USD 45.12 Million by 2020, at an estimated CAGR of 10.88% from 2015 to 2020. The technological advancements and industrialization combined with an increasing population in developing economies, increasing demand in various applications such as design & …
- 世界のコネクティッド健康M2Mサービス市場動向(2014-2018)TechNavio's analysts forecast the Global Connected Health M2M Services Market to grow at a CAGR of 30.08 percent over the period 2013-2018. One of the key factors contributing to this market growth is an increase in aging population. The Global Connected Health M2M Services Market has also been witnessing the increasing demand for remote healthcare monitoring. However, the low quality of wireless …